vs

Side-by-side financial comparison of AMTECH SYSTEMS INC (ASYS) and Ginkgo Bioworks Holdings, Inc. (DNA). Click either name above to swap in a different company.

Ginkgo Bioworks Holdings, Inc. is the larger business by last-quarter revenue ($33.4M vs $19.0M, roughly 1.8× AMTECH SYSTEMS INC). On growth, AMTECH SYSTEMS INC posted the faster year-over-year revenue change (-22.2% vs -23.8%). AMTECH SYSTEMS INC produced more free cash flow last quarter ($3.8M vs $-47.7M). Over the past eight quarters, Ginkgo Bioworks Holdings, Inc.'s revenue compounded faster (-6.2% CAGR vs -13.6%).

Amtech Systems Inc is a global manufacturer of advanced thermal processing and automation equipment primarily serving the semiconductor, solar photovoltaic, and LED production sectors. Its product portfolio includes soldering, diffusion, and deposition systems, with key markets spanning North America, East Asia, and Western Europe, catering to leading electronic component and clean energy manufacturing clients.

Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It...

ASYS vs DNA — Head-to-Head

Bigger by revenue
DNA
DNA
1.8× larger
DNA
$33.4M
$19.0M
ASYS
Growing faster (revenue YoY)
ASYS
ASYS
+1.6% gap
ASYS
-22.2%
-23.8%
DNA
More free cash flow
ASYS
ASYS
$51.5M more FCF
ASYS
$3.8M
$-47.7M
DNA
Faster 2-yr revenue CAGR
DNA
DNA
Annualised
DNA
-6.2%
-13.6%
ASYS

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
ASYS
ASYS
DNA
DNA
Revenue
$19.0M
$33.4M
Net Profit
$108.0K
Gross Margin
44.8%
Operating Margin
4.1%
-211.9%
Net Margin
0.6%
Revenue YoY
-22.2%
-23.8%
Net Profit YoY
-65.4%
EPS (diluted)
$0.01
$-1.41

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASYS
ASYS
DNA
DNA
Q4 25
$19.0M
$33.4M
Q3 25
$19.8M
$38.8M
Q2 25
$19.6M
$49.6M
Q1 25
$15.6M
$48.3M
Q4 24
$24.4M
$43.8M
Q3 24
$24.1M
$89.0M
Q2 24
$26.7M
$56.2M
Q1 24
$25.4M
$37.9M
Net Profit
ASYS
ASYS
DNA
DNA
Q4 25
$108.0K
Q3 25
$1.1M
$-80.8M
Q2 25
$106.0K
$-60.3M
Q1 25
$-31.8M
$-91.0M
Q4 24
$312.0K
Q3 24
$-536.0K
$-56.4M
Q2 24
$438.0K
$-217.2M
Q1 24
$970.0K
$-165.9M
Gross Margin
ASYS
ASYS
DNA
DNA
Q4 25
44.8%
Q3 25
44.4%
Q2 25
46.7%
Q1 25
-2.1%
Q4 24
38.4%
Q3 24
40.7%
Q2 24
36.5%
Q1 24
33.2%
Operating Margin
ASYS
ASYS
DNA
DNA
Q4 25
4.1%
-211.9%
Q3 25
9.3%
-231.8%
Q2 25
4.7%
-132.1%
Q1 25
-202.7%
-184.1%
Q4 24
1.4%
-236.3%
Q3 24
0.1%
-62.0%
Q2 24
3.1%
-396.7%
Q1 24
5.4%
-469.1%
Net Margin
ASYS
ASYS
DNA
DNA
Q4 25
0.6%
Q3 25
5.4%
-207.9%
Q2 25
0.5%
-121.6%
Q1 25
-204.2%
-188.2%
Q4 24
1.3%
Q3 24
-2.2%
-63.3%
Q2 24
1.6%
-386.4%
Q1 24
3.8%
-437.3%
EPS (diluted)
ASYS
ASYS
DNA
DNA
Q4 25
$0.01
$-1.41
Q3 25
$0.08
$-1.45
Q2 25
$0.01
$-1.10
Q1 25
$-2.23
$-1.68
Q4 24
$0.02
$-1.91
Q3 24
$-0.04
$-1.08
Q2 24
$0.03
$-4.23
Q1 24
$0.07
$-3.32

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASYS
ASYS
DNA
DNA
Cash + ST InvestmentsLiquidity on hand
$22.1M
$422.6M
Total DebtLower is stronger
$162.0K
Stockholders' EquityBook value
$54.1M
$508.6M
Total Assets
$94.1M
$1.1B
Debt / EquityLower = less leverage
0.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASYS
ASYS
DNA
DNA
Q4 25
$22.1M
$422.6M
Q3 25
$17.9M
$495.5M
Q2 25
$15.6M
$559.4M
Q1 25
$13.4M
$325.3M
Q4 24
$13.2M
$561.6M
Q3 24
$11.1M
$616.2M
Q2 24
$13.2M
$730.4M
Q1 24
$13.0M
$840.4M
Total Debt
ASYS
ASYS
DNA
DNA
Q4 25
$162.0K
Q3 25
$168.0K
Q2 25
$127.0K
Q1 25
$135.0K
Q4 24
$161.0K
Q3 24
$189.0K
Q2 24
$177.0K
Q1 24
$65.0K
Stockholders' Equity
ASYS
ASYS
DNA
DNA
Q4 25
$54.1M
$508.6M
Q3 25
$53.4M
$559.8M
Q2 25
$51.7M
$613.0M
Q1 25
$51.0M
$647.4M
Q4 24
$82.4M
$716.1M
Q3 24
$82.4M
$797.9M
Q2 24
$81.7M
$833.1M
Q1 24
$80.9M
$987.3M
Total Assets
ASYS
ASYS
DNA
DNA
Q4 25
$94.1M
$1.1B
Q3 25
$92.9M
$1.2B
Q2 25
$89.5M
$1.2B
Q1 25
$83.4M
$1.3B
Q4 24
$117.8M
$1.4B
Q3 24
$119.3M
$1.5B
Q2 24
$127.1M
$1.6B
Q1 24
$116.5M
$1.6B
Debt / Equity
ASYS
ASYS
DNA
DNA
Q4 25
0.00×
Q3 25
0.00×
Q2 25
0.00×
Q1 25
0.00×
Q4 24
0.00×
Q3 24
0.00×
Q2 24
0.00×
Q1 24
0.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASYS
ASYS
DNA
DNA
Operating Cash FlowLast quarter
$4.1M
$-47.7M
Free Cash FlowOCF − Capex
$3.8M
$-47.7M
FCF MarginFCF / Revenue
20.2%
-142.8%
Capex IntensityCapex / Revenue
1.5%
0.0%
Cash ConversionOCF / Net Profit
37.99×
TTM Free Cash FlowTrailing 4 quarters
$8.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASYS
ASYS
DNA
DNA
Q4 25
$4.1M
$-47.7M
Q3 25
$2.3M
$-31.6M
Q2 25
$2.5M
$-40.3M
Q1 25
$210.0K
$-51.5M
Q4 24
$2.9M
$-42.4M
Q3 24
$879.0K
$-103.5M
Q2 24
$3.7M
$-84.4M
Q1 24
$336.0K
$-89.3M
Free Cash Flow
ASYS
ASYS
DNA
DNA
Q4 25
$3.8M
$-47.7M
Q3 25
$2.0M
Q2 25
$2.0M
$-40.3M
Q1 25
$201.0K
$-59.1M
Q4 24
$2.7M
$-56.1M
Q3 24
$447.0K
$-118.6M
Q2 24
$322.0K
$-111.4M
Q1 24
$-884.0K
$-96.0M
FCF Margin
ASYS
ASYS
DNA
DNA
Q4 25
20.2%
-142.8%
Q3 25
10.2%
Q2 25
10.1%
-81.2%
Q1 25
1.3%
-122.4%
Q4 24
11.2%
-128.0%
Q3 24
1.9%
-133.2%
Q2 24
1.2%
-198.2%
Q1 24
-3.5%
-252.9%
Capex Intensity
ASYS
ASYS
DNA
DNA
Q4 25
1.5%
0.0%
Q3 25
1.2%
0.0%
Q2 25
2.8%
0.1%
Q1 25
0.1%
15.8%
Q4 24
0.6%
31.3%
Q3 24
1.8%
16.9%
Q2 24
12.5%
48.1%
Q1 24
4.8%
17.7%
Cash Conversion
ASYS
ASYS
DNA
DNA
Q4 25
37.99×
Q3 25
2.12×
Q2 25
23.89×
Q1 25
Q4 24
9.19×
Q3 24
Q2 24
8.35×
Q1 24
0.35×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASYS
ASYS

Thermal Processing Solutions$14.0M74%
Semiconductor Fabrication Solutions$5.0M26%

DNA
DNA

Cell Engineering Segment$26.0M78%
Other$7.4M22%

Related Comparisons